Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05 | Zendy

Gregory E. Steinkraus | Zendy; Roger L. White | Zendy; Lawrence V. Friedrich | Zendy

Open Access

Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05

Author(s) -

Gregory E. Steinkraus,

Roger L. White,

Lawrence V. Friedrich

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm258

Subject(s) - daptomycin , linezolid , etest , vancomycin , microbiology and biotechnology , staphylococcus aureus , medicine , methicillin resistant staphylococcus aureus , minimum inhibitory concentration , antibiotics , biology , bacteria , genetics

To assess whether methicillin-resistant Staphylococcus aureus (MRSA) vancomycin MIC shifts (MIC creep) at a tertiary care institution occurred that may have gone undetected using traditional susceptibility markers (percentage susceptible, MIC(50), MIC(90)) over a 5 year period. Additionally, MIC trends were evaluated for oxacillin, linezolid and daptomycin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research